Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex's VX-661 Has Positive Outlook Despite Futility Finding

Executive Summary

Although a study testing a combo of the company's cystic fibrosis drug Kalydeco and the investigational VX-661 in patients with minimal CFTR function was ended due to futility, Vertex is on pace for a 2017 filing of the combo in three other CF subpopulations.

Advertisement

Related Content

Vertex Plays Defense In CF With Concert Deal
Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way
Pfizer's Medivation Buyout: One-Off Deal Or Start Of A Biopharma Spending Spree?
Keeping Track: FDA Turns Down Telesta's MCNA, Broader Use Of Vertex' Kalydeco
Vertex Gears Up For Next Generation In CF Therapy
Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex
Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097135

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel